Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG0070 and Nivolumab in Cisplatin-Ineligible MIBC
NCT04610671Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2020
- Primary completion
- Jul 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cretostimogene grenadenorepvec in bladder carcinoma, sponsored by Moffitt Cancer Center. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 24 months. Started Oct 2020; status: completed.
02
Drugs
cretostimogene grenadenorepvec
03
Conditions
bladder carcinoma
Beyond the preview
Go deeper on NCT04610671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610671.